CorMedix Misses on EPS, Beats on Revenue, Nears Heron Deal

CorMedix reported a third-quarter loss of $0.19 per share on Thursday, missing analyst consensus of a $0.12 loss by seven cents. Revenue told a different story: $54.52 million against expectations of $51.76 million, a beat of roughly 5.3 percent. The stock closed the session at $4.84, down $0.46 on volume of 2,947,331 shares — nearly double its average of 1,614,626.

The quarter's profitability metrics remain unusually strong for a commercial-stage biopharma. Return on equity came in at 40.52 percent, and net margin at 40.49 percent.

What did management tell investors on the call?

The headline development sits outside the quarter itself. CorMedix agreed to acquire substantially all of Heron Therapeutics' assets, a deal management expects to add approximately $125 million to $150 million in 2027 revenue. Management also projects $45 million to $60 million in annualized cost synergies by the end of 2027, with the transaction immediately accretive to earnings and free cash flow, subject to closing conditions.

On the core franchise, the picture is mixed. DefenCath utilization at large dialysis customers largely held steady after the post-TDAPA reimbursement change, and management expects the 2027 add-on payment to remain above the current $2.37 rate. Still, the quarterly payment framework and unresolved customer pricing and Medicare Advantage arrangements mean the company cannot yet provide 2027 DefenCath guidance.

DefenCath sales for the quarter came in at $17.2 million, a figure that includes a $5 million favorable adjustment to sales allowances. Adjusted EBITDA reached $3.1 million.

Where does guidance stand?

CorMedix maintained its 2026 revenue outlook of $325 million to $345 million and narrowed adjusted EBITDA guidance to $130 million to $140 million. The balance sheet supports the plan: the company ended the quarter with $355.2 million in cash.

Two pipeline items round out the picture:

• The FDA accepted REZZAYO's supplemental application for prophylaxis with priority review, setting a target decision in the first quarter of 2027. CorMedix is preparing for a potential launch in the second half of 2027 if approved.
• Enrollment in the phase III TPN study for DefenCath remains meaningfully behind schedule despite added sites and a protocol amendment. Management is evaluating alternative FDA pathways and expects to decide on the study strategy before its next quarterly update.

How did the market and analysts respond?

The shares have traveled a long way down from their 52-week high of $13.02; the one-year low sits at $4.82, a level the stock grazed intraday on Thursday. The technical backdrop mirrors the pressure: a 50-day moving average of $7.33 and a 200-day moving average of $7.60, both far above the print.

Valuation and balance-sheet measures:

• Market capitalization: $377.64 million
• Price-to-earnings ratio: 2.26; PEG ratio: 1.00
• Beta: 1.48
• Quick ratio: 2.36; current ratio: 2.56; debt-to-equity: 0.31

Analyst action clustered early in the week. Needham & Company raised its target from $12.00 to $14.00 with a buy rating. Royal Bank of Canada lifted its target from $14.00 to $15.00 and kept an outperform rating. UBS Group set a $19.00 target. Oppenheimer initiated coverage on Wednesday, September 23, with an outperform rating and a $15.00 objective. Weiss Ratings moved the other way, cutting the stock from hold (c+) to hold (c).

In aggregate, eight analysts rate the shares a Buy and two a Hold, producing a consensus of Moderate Buy with an average price target of $15.44 — more than three times Thursday's close.

What is CorMedix, in plain terms?

CorMedix Inc. develops products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin, approved by the FDA to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter. The company expanded in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

The takeaway: an EPS miss against a revenue beat, a cash-rich balance sheet, and a Heron acquisition that reframes 2027 — while the stock trades near its yearly low and analysts hold targets far above it.